Verastem (VSTM) Intangibles (2018 - 2026)

Verastem (VSTM) posted quarterly Intangibles of $17.1 million for Q1 2026, up 4.24% quarter-over-quarter from $16.4 million in Q4 2025.

Analysis

Verastem (VSTM) Intangibles (2018 - 2026) Analysis & Trends

Verastem's Intangibles history runs 5 years deep, the most recent figure standing at $17.1 million for Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $17.1 million; the TTM figure through Mar 2026 stood at $17.1 million (changed N/A YoY), while the FY2025 annual figure was $16.4 million, changed N/A from the prior year.
Intangibles for Q1 2026 stood at $17.1 million, up from $16.4 million in the prior quarter.
The five-year high for Intangibles was $17.1 million in Q3 2025, with the low at $15.6 million in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	63.28 Mn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	60.96 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	93.49 Mn
10	Verastem	814.94 Mn	678.59 Mn	36.32 Mn	17.12 Mn

Historic Data

Download Data